Novo Nordisk cuts cash prices for Wegovy and Ozempic

Novo Nordisk It said Monday it had reduced direct-to-consumer prices for the blockbuster weight-loss drug Wegovy and its diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to make the treatments more accessible.

The Danish pharmaceutical company is reducing the price of the drugs for current cash-paying patients to $349 per month from $499 per month. But Novo Nordisk said the cash cost for the highest dose of Ozempic will still be $499 per month.

Also on Monday, Novo Nordisk launched a temporary introductory offer, which will allow new cash-paying patients to access the lowest two doses of Wegovy and Ozempic for $199 per month for the first two months of treatment. After that period, people move to the new standard direct-to-consumer monthly rate. The company’s introductory offer ends on March 31.

These announcements come days after President Donald Trump concluded deals with Novo Nordisk and its main competitor Eli Lilly To make their popular GLP-1 drugs easier for Americans to access and afford. These agreements will include lowering the prices the government pays for drugs, offering Medicare coverage for obesity drugs for the first time to some patients and offering discounted medications on the government’s new direct-to-consumer website launched in January called TrumpRx.

“Our new savings offers provide immediate impact, resulting in greater cost savings for those who currently do not have coverage or choose to pay on their own,” Dave Moore, president of Novo Nordisk’s U.S. operations, said in a statement. “It’s part of a larger strategy to expand access that includes building relationships with telehealth providers and major retailers, expanding coverage, and working with the administration to lower costs for people with chronic diseases like obesity.”

The Trump administration said initial doses for existing injections like Wegovy and Eli Lilly’s weight-loss drug Zepbound would be $350 a month on TrumpRx, but would drop to $245 a month over two years.

On the day the deals were announced, Eli Lilly said it would cut prices by $50 on its direct-to-consumer platform, LillyDirect, which already offers Zepbound at a discount to patients who pay with cash. The Zepbound Multi-Dose Pen will be available for $299 per month at the lowest dose, with additional doses priced at $449 per month.

Novo Nordisk’s new cash offerings are available through Wegovy.com or Ozempic.com, the company’s direct-to-consumer pharmacy, NovoCare, and other participating organizations and telehealth providers that work directly with the drugmaker, including Costco, GoodRxWeightWatchers, Ro, LifeMD, and eMed.